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Abstract
IMPORTANCE—Bilateral mastectomy is increasingly used to treat unilateral breast cancer. 
Because it may have medical and psychosocial complications, a better understanding of its use and 
outcomes is essential to optimizing cancer care.
OBJECTIVE—To compare use of and mortality after bilateral mastectomy, breast-conserving 
therapy with radiation, and unilateral mastectomy.
DESIGN, SETTING, AND PARTICIPANTS—Observational cohort study within the 
population-based California Cancer Registry; participants were women diagnosed with stages 0–
III unilateral breast cancer in California from 1998 through 2011, with median follow-up of 89.1 
months.
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MAIN OUTCOMES AND MEASURES—Factors associated with surgery use (from 
polytomous logistic regression); overall and breast cancer–specific mortality (from propensity 
score weighting and Cox proportional hazards analysis).
RESULTS—Among 189 734 patients, the rate of bilateral mastectomy increased from 2.0% (95% 
CI, 1.7%–2.2%) in 1998 to 12.3% (95% CI, 11.8%–12.9%) in 2011, an annual increase of 14.3% 
(95% CI, 13.1%–15.5%); among women younger than 40 years, the rate increased from 3.6% 
(95% CI, 2.3%–5.0%) in 1998 to 33% (95% CI, 29.8%–36.5%) in 2011. Bilateral mastectomy was 
more often used by non-Hispanic white women, those with private insurance, and those who 
received care at a National Cancer Institute (NCI)–designated cancer center (8.6% [95% CI, 
8.1%–9.2%] among NCI cancer center patients vs 6.0% [95% CI, 5.9%–6.1%] among non-NCI 
cancer center patients; odds ratio [OR], 1.13 [95% CI, 1.04–1.22]); in contrast, unilateral 
mastectomy was more often used by racial/ethnic minorities (Filipina, 52.8% [95% CI, 51.6%–
54.0%]; OR, 2.00 [95% CI, 1.90–2.11] and Hispanic, 45.6% [95% CI, 45.0%–46.2%]; OR, 1.16 
[95% CI, 1.13–1.20] vs non-Hispanic white, 35.2% [95% CI, 34.9%–35.5%]) and those with 
public/Medicaid insurance (48.4% [95% CI, 47.8%–48.9%]; OR, 1.08 [95% CI, 1.05–1.11] vs 
private insurance, 36.6% [95% CI, 36.3%–36.8%]). Compared with breast-conserving surgery 
with radiation (10-year mortality, 16.8% [95% CI, 16.6%–17.1%]), unilateral mastectomy was 
associated with higher all-cause mortality (hazard ratio [HR], 1.35 [95% CI, 1.32–1.39]; 10-year 
mortality, 20.1% [95% CI, 19.9%–20.4%]). There was no significant mortality difference 
compared with bilateral mastectomy (HR, 1.02 [95% CI, 0.94–1.11]; 10-year mortality, 18.8% 
[95% CI, 18.6%–19.0%]). Propensity analysis showed similar results.
CONCLUSIONS AND RELEVANCE—Use of bilateral mastectomy increased significantly 
throughout California from 1998 through 2011 and was not associated with lower mortality than 
that achieved with breast-conserving surgery plus radiation. Unilateral mastectomy was associated 
with higher mortality than were the other 2 surgical options.
Randomized trials have demonstrated similar survival for patients with early-stage breast 
cancer treated with breast-conserving surgery and radiation or with mastectomy.1,2 However, 
older data show increasing use of mastectomy, and particularly bilateral mastectomy, among 
US patients with breast cancer.3–5 Bilateral mastectomy represents both treatment (for the 
affected breast) and prevention (for the contralateral breast), with the uncommon exception 
of patients having bilateral tumors. The causes of the increasing use of bilateral mastectomy 
are unknown; one possibility is the dissemination of sensitive diagnostic tests such as breast 
magnetic resonance imaging and genetic testing of BRCA1 (unigene cluster number Hs.
194143) and BRCA2 (unigene cluster number Hs.34012).4,6 Although it may be cited as a 
justification for bilateral mastectomy, evidence for a survival benefit appears limited to rare 
patient subgroups, including women with BRCA1/2 mutations or strong family history of 
cancer.7–9
Because bilateral mastectomy is an elective procedure for unilateral breast cancer and may 
have detrimental effects in terms of complications and associated costs10,11 as well as body 
image and sexual function,12,13 a better understanding of its use and outcomes is crucial to 
improving cancer care. Because patients’ preferences drive its use, patients are unlikely to 
accept randomization to a less extensive surgical procedure in a clinical trial; thus, 
observational studies offer a feasible alternative to address an important clinical question. To 
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minimize selection bias, we designed a population-based study of the use and outcomes of 
bilateral mastectomy compared with other surgical treatments, using the California Cancer 
Registry (CCR, part of the National Cancer Institute [NCI] Surveillance, Epidemiology and 
End Results [SEER] program), which comprises about 99% of all breast cancer cases 
statewide.
Methods
Case Ascertainment and Data Collection
The study population consisted of all female California residents newly diagnosed with a 
first primary breast cancer (International Classification of Diseases–Oncology, 3rd edition, 
morphology codes C50.0–50.9), of American Joint Commission on Cancer stages 0–III, 
from January 1, 1998, through December 31, 2011. Approval for human subjects research 
was obtained from the Cancer Prevention Institute of California institutional review board. 
We obtained CCR data routinely abstracted from medical records on age at diagnosis, race/
ethnicity (from patients’ medical records and registry categorization; assessed because prior 
research indicates that the use of and survival after surgical procedures vary by race/
ethnicity, and because we aimed to evaluate these associations in a population-based 
context), marital status, stage, tumor grade, tumor size, histology, lymph node involvement, 
metastasis, and biomarkers.14 Tumors with histologic morphology codes 8500–8508 and 
8521–8523 were coded as ductal and those with codes 8520 and 8524–8525 as lobular. We 
also obtained CCR information on initial treatment (surgery, chemotherapy, and radiation 
therapy), primary health insurance, census block group of residence at diagnosis, and vital 
status (determined by CCR through hospital follow-up and database linkages, including the 
Social Security Administration) as of December 31, 2010, and, for the deceased, the 
underlying cause of death.
Tumor Biomarker Information
Estrogen-receptor and progesterone-receptor status were each categorized as positive (≥5% 
nuclear staining), negative, borderline, not tested, not recorded, or unknown. Tumors were 
considered estrogen receptor–/progesterone receptor–positive if they were estrogen 
receptor–positive, progester-one receptor–positive, or both, and as estrogen receptor–/
progesterone receptor–negative if both were negative. Given that CCR did not systematically 
collect v-erb-b2 avian erythroblastic leukemia viral oncogene homologue 2 (ERBB2, also 
known as HER-2/neu, unigene cluster number Hs.446352) testing results before 2006, 
ERBB2 data are not included.
Neighborhood Socioeconomic Information
For each case, we assigned a previously developed measure of neighborhood socioeconomic 
status (SES). For cases diagnosed in 1998–2005, we used a measure of neighborhood-level 
SES quintiles based on distribution across California, incorporating block group-level data 
from the 2000 Census on income, education, housing costs, and occupation.15 For cases 
diagnosed in 2006–2010, we used data from the American Community Survey of the US 
Census to derive a similar index.
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Hospital-Level Information
The CCR records the facility reporting each case. Using the aforementioned index, we 
determined the SES distribution of all cases for each facility and identified facilities that 
were NCI–designated cancer centers.
Statistical Analysis
We used polytomous logistic regression to model surgery use. Survival time was measured 
in days from diagnosis to death. Women who died from other causes were censored at time 
of death for the analysis of breast cancer–specific mortality. Women alive at the time of last 
follow-up or December 31, 2010, were censored then. We used Cox proportional hazards to 
model the association of various factors with overall and breast cancer–specific mortality. 
The proportional hazards assumption was confirmed by testing the correlation of Schoenfeld 
residuals with time. For both models (surgery use and mortality), covariates included age, 
race/ethnicity, tumor size, grade, histology, nodal and estrogen receptor/progesterone 
receptor status, receipt of adjuvant chemotherapy and radiation, neighbor hood SES quintile, 
marital and insurance status, the SES composition of patients at the reporting hospital, care 
at an NCI-designated cancer center, and diagnosis year. Stage was included as a stratifying 
variable in the Cox regression, allowing baseline hazards to vary by stage. Multicol-linearity 
in the models was assessed using the variance inflation factor. We did not test for a priori 
interactions but did conduct stratified analyses by age and stage. Missing data were coded as 
unknown and retained as a separate category for analyses.
We used SAS version 9.3 for all analyses except those of surgical use trends, for which we 
used Joinpoint (Joinpoint Regression Program version 4.0.4 [Statistical Research and 
Applications Branch, NCI]). This program uses Monte Carlo Permutation tests to model 
data and identify up to 3 points (“joinpoints”) at which there was a statistically significant 
change in linear trend.16 Results of joinpoint analysis were used to inform grouping of 
diagnosis years in logistic regression analysis.
Propensity score analyses defined surgery type as the patient attribute for which scores were 
calculated.17 We used generalized boosting models, a nonparametric machine-learning 
classifier, in the R package twang, setting the search limit to 15 000 trees.18 All independent 
variables in Table 1 and Table 2 were used to calculate per-patient scores, except 3 variables 
highly correlated with others (radiation therapy with surgery type; chemotherapy and 
adjuvant treatment with administration of chemotherapy before or after the surgical 
procedure).
We used graphical analysis to assess the postbalance maximum standardized effect 
difference for each variable17 and calculated weights for the average treatment effect 
(average outcome for the whole population after one surgery vs another); and average 
treatment effect for those treated (average out come for those treated after one surgery vs 
another). The svykm and svylogrank functions from the survey package19 were used to 
calculate weighted Kaplan-Meier curves and P values; the svycoxph function was used for 
weighted Cox proportional hazard models, with outcome regressed on treatment and 
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stratified by stage. Weighted CIs for mortality rates were calculated by the survfit function in 
the R survival package.
Results
Patient Characteristics
A total of 291 117 stages 0–III breast cancer cases were diagnosed and reported to CCR 
from January 1, 1998, through December 31, 2011. Cases were excluded if missing essential 
data for categorization or if ineligible for breast-conserving surgery with radiation according 
to practice guide lines,20 as follows: diagnosed by death certificate or autopsy only (n = 33); 
tumor larger than 5 cm or unknown, microscopic or diffuse tumor, Paget disease of breast or 
mammographic diagnosis only, or inflammatory carcinoma (n = 41 853); no pathology 
report confirmation (n = 283); unknown lymph node involvement (n = 1771); surgery other 
than bilateral mastectomy, breast-conserving surgery with radiation, or unilateral 
mastectomy (n = 52 343); and diagnosis of bilateral tumors or a second primary breast tumor 
within 60 days (n = 5100), resulting in 189 734 women included in analyses of surgery use. 
Mortality analyses excluded women diagnosed after 2010 because of incomplete mortality 
data for 2011 (n = 14 331), those having zero or invalid survival time (n = 11), and those 
having unknown cause of death (n = 475). Mortality analyses included 174 917 women; 
median follow-up time was 89.1 months (inter quartile range, 54.8–129.9 months).
The proportions of all patients who underwent each surgery were 6.2% (95% CI, 6.1%–
6.3%) for bilateral mastectomy, 55.0% (95%, 54.8%–55.3%) for breast-conserving surgery 
with radiation; and 38.8% (95% CI, 38.6%–39.0%) for unilateral mastectomy (Table 1 and 
eTable in the Supplement). Among all patients, the rate of bilateral mastectomy increased 
from 2.0% (95% CI, 1.7%–2.2%) in 1998 to 12.3% (95% CI, 11.8%–12.9%) in 2011, an 
annual increase of 14.3% (95% CI, 13.1%–15.5%)(Table 2 and eTable). The increase in 
bilateral mastectomy rate was greatest among women younger than 40 years: the rate 
increased from 3.6% (95% CI, 2.3%–5.0%) in 1998 to 33.0% (95% CI, 29.8%–36.5%) in 
2011, increasing by 17.6% (95% CI, 14.9%–20.4%) annually. Use of unilateral mastectomy 
declined in all age groups (Figure 1).
Multiple Regression Analysis of Characteristics Associated With Surgical Type
Factors associated with having undergone bilateral mastectomy (vs breast-conserving 
surgery with radiation) included age younger than 50 years, non-Hispanic white race/
ethnicity, larger tumor size, nodal involvement, lobular histology, higher grade or estrogen 
receptor–/progesterone receptor–negative status, care at a hospital predominantly serving 
patients with lower SES or at an NCI-designated cancer center, having higher neighborhood 
SES, and recent diagnosis. Factors inversely associated with having undergone bilateral 
mastectomy (vs breast-conserving surgery with radiation) included age 65 years or older, 
minority race/ethnicity, receipt of adjuvant therapy, married status, and insurance type other 
than private (Table 3).
Characteristics associated with having undergone unilateral mastectomy (vs breast-
conserving surgery plus radiation) included diagnosis at age other than 50 to 64 years, 
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Asian, Hispanic, and American Indian race/ethnicity (with notable associations for Filipina 
and Hispanic women vs non-Hispanic white women), larger tumor size, nodal involvement, 
lobular histology, higher grade, estrogen receptor–/progesterone receptor–negative status, 
married status, public/Medicaid insurance, or care at a hospital predominantly serving 
patients of lower SES (Table 3). Factors inversely associated with having unilateral 
mastectomy (vs breast-conserving surgery with radiation) included black race, receipt of 
adjuvant therapy, care at an NCI-designated cancer center, higher neighborhood SES, and 
recent diagnosis.
Multiple Regression Analysis of Mortality After Surgery
Compared with breast-conserving surgery with radiation, bilateral mastectomy was not 
associated with a mortality difference (hazard ratio [HR], 1.02 [95% CI, 0.94–1.11]), 
whereas unilateral mastectomy was associated with higher mortality (HR, 1.35[95% CI, 
1.32–1.39]) (Table 4). Other factors associated with overall mortality included age 65 years 
or older or younger than 40 years, black race, larger tumor size, nodal involvement, higher 
grade, estrogen receptor–/progesterone receptor–negative status, lower neighborhood SES, 
unmarried status, having Medicare or public/Medicaid insurance, and receiving care at a 
hospital predominantly serving patients of lower SES. Higher mortality was associated with 
unilateral mastectomy in all age groups. Similar mortality between bilateral mastectomy and 
breast-conserving surgery with radiation was observed in all age groups except women 65 
years or older, whose survival was slightly better after breast-conserving surgery with 
radiation. Findings were similar for breast cancer–specific mortality (Table 5). Compared 
with unilateral mastectomy, bilateral mastectomy was associated with lower overall 
mortality (HR, 0.75 [95% CI, 0.70–0.82]) and breast cancer–specific mortality (HR, 0.85 
[95% CI, 0.76–0.94]).
Propensity Analysis of Marginal Mortality After Surgery
Figure 2A shows estimated mortality among all patients if surgical procedure were randomly 
assigned (analysis of average treatment effect). The estimated 10-year mortality rates were 
18.8% (95% CI, 18.6%–19.0%) for bilateral mastectomy, 16.8% (95% CI, 16.6%–17.1%) 
for breast-conserving surgery with radiation, and 20.1% (95%CI, 19.9%–20.4%) for 
unilateral mastectomy. Figure 2B–D shows estimated mortality from another surgical 
procedure among patients who had a specific surgical procedure (analysis of average 
treatment effect for those treated). For patients receiving breast-conserving surgery with 
radiation, bilateral mastectomy would have resulted in marginally higher mortality, on 
average, and unilateral mastectomy in higher mortality. For patients receiving unilateral 
mastectomy, bilateral mastectomy would have resulted in unchanged mortality and breast-
conserving surgery with radiation in lower mortality. For patients receiving bilateral 
mastectomy, breast-conserving surgery with radiation would have resulted in unchanged 
mortality and unilateral mastectomy in higher mortality. Proportional hazards regression 
models showed similar results (Table 6).
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Discussion
This observational study comprising 189 734 women with unilateral early-stage breast 
cancer compared 3 surgical treatments and found a substantial increase in the rate of 
bilateral mastectomy throughout California from 1998 through 2011. To our knowledge, this 
is the first side-by-side comparison of all 3 common surgical treatments for early-stage 
breast cancer. Previous SEER studies have compared 2 treatments at a time: some reported a 
survival advantage with bilateral vs unilateral mastectomy21,22 and others reported improved 
survival after breast-conserving surgery with radiation compared with unilateral 
mastectomy.23,24 By comparing all 3 surgical options for a patient with early-stage breast 
cancer, we found no mortality benefit associated with bilateral mastectomy compared with 
breast-conserving surgery, and higher mortality associated uniquely with unilateral 
mastectomy.
For the surgical treatment of early-stage breast cancer, available randomized trial data are 
limited to those showing no survival difference between unilateral mastectomy and breast-
conserving surgery.1,2 There is no randomized trial evidence to inform whether bilateral 
mastectomy improves survival, and it is unlikely that such a trial will ever be performed. 
Thus, conclusions about surgical treatments must rely on observational studies that compare 
the effectiveness of different procedures in practice21,22,25,26; however, a recent meta-
analysis judged the existing data inadequate to enable conclusions about the effect of 
bilateral mastectomy on survival.27 Patient selection attributable to unmeasured factors 
probably explains much of the higher mortality that we observed with unilateral mastectomy 
relative to the other 2 surgical procedures. In prior SEER-based studies, both we24 and 
Agarwal et al23 reported worse survival associated with unilateral mastectomy vs breast-
conserving surgery with radiation, results that persisted after propensity analysis. We agree 
with previous suggestions that patients with tumor features suggesting poor prognosis, such 
as lymphovascular invasion or extranodal extension, which SEER does not record and for 
which we cannot control, are more likely to undergo unilateral mastectomy than breast 
conservation and also to experience worse survival.23,24 The current study offers another 
potential explanation, namely confounding related to sociodemographic differences between 
women who underwent bilateral mastectomy and women who underwent unilateral 
mastectomy.
Women who underwent bilateral mastectomy were more likely to be non-Hispanic white and 
privately insured, to live in high SES neighborhoods, and to be treated in NCI-designated 
cancer centers. By contrast, women who underwent unilateral mastectomy were more likely 
to be Asian, Hispanic, or non-Hispanic American Indian/other/unknown; to have public/
Medicaid insurance, and to be treated in hospitals serving patients of lower SES; they were 
less likely to live in high SES neighborhoods or to be treated in NCI-designated cancer 
centers. Cancer registry data lack details about comorbidities and specific regimens of 
endocrine, radiation, and chemotherapy. However, prior studies enriched for clinical data, 
including our own within the Kaiser Permanente Northern California health care system, 
reported treatment-limiting comorbidities (for example, diabetes and myocardial infarction) 
and reduced treatment intensity among the same racial/ethnicminority, low SES patients who 
most frequently under went unilateral mastectomy in our current study.28–30 In addition to 
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signifying unmeasured poor prognostic factors,21,22 unilateral mastectomy might correlate 
with subtle disparities in effective access (for example, diabetic neuropathy that limits 
chemotherapy dosing; lack of transportation to the postsurgical radiation treatments required 
for breast conservation) that we could not identify using registry data and that may mediate 
higher mortality. By contrast, patterns of bilateral mastectomy use suggest that affluent non-
Hispanic white women, women of high SES, or both seek more aggressive preventive care, 
consistent with reported associations between greater use of expensive diagnostic tests (such 
as breast MRI and genetic testing) and bilateral mastectomy within this patient subgroup.4,31
The increase in bilateral mastectomy use despite the absence of supporting evidence has 
puzzled clinicians and health policy makers. Proposed explanations include the increasing 
use of highly sensitive breast magnetic resonance imaging, with increases in anxiety-
producing recall and biopsy rates that may drive patients to undergo preventive 
surgery,6,31,32 and the dissemination of genetic testing, which facilitates identification of 
high-risk patients who benefit from bilateral mastectomy.7,8,33 Although fear of cancer 
recurrence may prompt the decision for bilateral mastectomy, such fear usually exceeds the 
estimated risk.34,35 Other studies found recurrence fears less influential than aesthetic 
considerations, notably those that arise with new reconstruction approaches that achieve 
cosmetic symmetry through bilateral tissue flap placement.6,36 Because cosmesis may be 
inferior if both breasts are not reconstructed simultaneously, these new approaches 
encourage use of immediate bilateral mastectomy. We found that bilateral mastectomy use 
over time increased most among patients younger than 40 years at diagnosis, which may be 
attributable to their relatively high probability of carrying genetic mutations (an evidence-
based indication for bilateral mastectomy)37 or to the greater likelihood that they have young 
children and may therefore seek maximal intervention in hope of extending their lives (an 
emotional rather than evidence-based decision).34,35,38 Although some studies reported 
patient satisfaction after bilateral mastectomy,39 others observed deleterious effects on body 
image, sexual function, and quality of life12; moreover, repeat operations and complications 
(including flap failure, necrosis, and infection) are substantially more common with bilateral 
mastectomy than with other surgical procedures.10,11
In a time of increasing concern about overtreatment,40 the risk-benefit ratio of bilateral 
mastectomy warrants careful consideration and raises the larger question of how physicians 
and society should respond to a patient’s preference for a morbid, costly intervention of 
dubious effectiveness.
Our study used a population-based statewide data set, multiple regression analysis, and 
propensity scores. However, given its observational design, it cannot prove causation and 
may be subject to selection bias and uncontrolled confounding. As discussed above, 
unmeasured patient selection factors related to cancer prognosis and access to care may 
explain the higher mortality observed with unilateral mastectomy. Other limitations include 
the lack of SEER data on diagnostic testing (eg, magnetic resonance imaging, genetic testing 
for BRCA1/2 and other inherited mutations, tumor analysis for ERBB2 amplification, and 
broader genomic profiling), details of systemic treatments, family cancer history, and 
comorbidities. Additional information gaps include patient preferences and physician 
recommendations, which influence surgical decisions.38 Future research with more 
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comprehensive data sets that integrate detailed clinical, treatment, and patient-reported 
information will be essential to advance understanding of breast surgery use and to enhance 
the quality of cancer care.
Conclusions
Among all women diagnosed with early-stage breast cancer in California, the percentage 
undergoing bilateral mastectomy increased substantially between 1998 and 2011, despite a 
lack of evidence supporting this approach. Bilateral mastectomy was not associated with 
lower mortality than breast-conserving surgery plus radiation, but unilateral mastectomy was 
associated with higher mortality than the other options. These results may inform decision-
making about the surgical treatment of breast cancer.
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Figure 1. 
Joinpoint Analysis Showing Time Trends in Use of Bilateral Mastectomy, Breast-
Conserving Surgery With Radiation, and Unilateral Mastectomy, According to Patient Age 
in Years at Breast Cancer Diagnosis
Data points indicate observed data.
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Figure 2. 
Propensity-Weighted Kaplan-Meier Plots of Estimated Mortality Among All Patients if 
Surgical Procedure Had Been Randomly Assigned and of Estimated Mortality if a Different 
Surgical Procedure Had Been Performed Among Patients Who Had Undergone a Specific 
Surgical Procedure
A, Estimated mortality among all patients if surgical procedure were randomly assigned 
(analysis of average treatment effect). B–D, Estimated mortality from another surgical 
procedure among patients who had a specific surgical procedure (analysis of average 
treatment effect for those treated). B, For patients receiving breast-conserving surgery with 
radiation, bilateral mastectomy would have resulted in marginally higher mortality, on 
average, and unilateral mastectomy in higher mortality. C, For patients receiving unilateral 
mastectomy, bilateral mastectomy would have resulted in unchanged mortality and breast-
conserving surgery with radiation in lower mortality. D, For patients receiving bilateral 
mastectomy, breast-conserving surgery with radiation would have resulted in unchanged 
mortality and unilateral mastectomy in higher mortality.
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Table 3
Multiple Regression Odds Ratios for Associations With Receipt of Bilateral Mastectomy or Unilateral 
Mastectomy vs Breast-Conserving Surgery With Radiation as the Reference Groupa
Variable
Odds Ratio (95% CI)
Bilateral Mastectomy vs Breast-
Conserving Surgery With Radiation
Unilateral Mastectomy vs Breast-
Conserving Surgery With Radiation
Race/ethnicity
 Non-Hispanic white 1 [Reference] 1 [Reference]
 Chinese 0.41 (0.35–0.48) 1.95 (1.84–2.08)
 Filipina 0.61 (0.54–0.70) 2.00 (1.90–2.11)
 Hispanic 0.63 (0.59–0.67) 1.16 (1.13–1.20)
 Japanese 0.63 (0.51–0.77) 1.40 (1.28–1.53)
 Non-Hispanic American Indian/other/unknown 0.76 (0.61–0.96) 1.23 (1.10–1.38)
 Non-Hispanic black 0.53 (0.47–0.59) 0.89 (0.85–0.94)
 Other Asian/Pacific Islander 0.64 (0.58–0.71) 1.88 (1.79–1.97)
Age at diagnosis, y
 <40 3.81 (3.55–4.08) 1.31 (1.25–1.38)
 40–49 2.00 (1.91–2.10) 1.15 (1.12–1.18)
 50–64 1 [Reference] 1 [Reference]
 ≥65 0.45 (0.42–0.48) 1.34 (1.30–1.38)
Tumor size
 Per centimeter 1.36 (1.34–1.39) 1.61 (1.60–1.63)
Lymph node involvement
 Negative 1 [Reference] 1 [Reference]
 Positive 1.66 (1.58–1.75) 2.16 (2.10–2.22)
Histology
 Ductal 1 [Reference] 1 [Reference]
 Lobular or with lobular component 2.19 (2.05–2.35) 1.36 (1.31–1.42)
 Other 0.89 (0.82–0.97) 0.96 (0.92–1.00)
Grade
 I 1 [Reference] 1 [Reference]
 II 1.17 (1.11–1.24) 1.18 (1.15–1.22)
 III 1.30 (1.22–1.38) 1.24 (1.20–1.28)
 Unknown 1.67 (1.52–1.84) 1.45 (1.38–1.52)
ER/PR status
 Positive 1 [Reference] 1 [Reference]
 Negative 1.12 (1.05–1.19) 1.17 (1.13–1.21)
 Unknown or borderline 1.53 (1.43–1.64) 1.53 (1.48–1.58)
Adjuvant treatment, chemotherapy, and/or radiation
 No 1 [Reference] 1 [Reference]
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Variable
Odds Ratio (95% CI)
Bilateral Mastectomy vs Breast-
Conserving Surgery With Radiation
Unilateral Mastectomy vs Breast-
Conserving Surgery With Radiation
 Yes 0.91 (0.86–0.95) 0.86 (0.84–0.89)
Neighborhood SES quintileb,c
 1 (lowest) 1 [Reference] 1 [Reference]
 2 1.10 (1.00–1.21) 0.91 (0.88–0.95)
 3 1.18 (1.08–1.29) 0.85 (0.82–0.89)
 4 1.22 (1.11–1.33) 0.80 (0.76–0.83)
 5 1.41 (1.29–1.55) 0.73 (0.70–0.76)
Marital status
 Not married 1 [Reference] 1 [Reference]
 Married 0.95 (0.91–0.99) 1.07 (1.05–1.10)
 Unknown 1.06 (0.92–1.22) 1.37 (1.28–1.47)
Insurance status
 Private 1 [Reference] 1 [Reference]
 Medicare 0.97 (0.88–1.06) 0.97 (0.93–1.00)
 Military 0.84 (0.68–1.04) 1.08 (0.97–1.21)
 Not insured or self-pay 0.78 (0.61–0.99) 1.08 (0.96–1.21)
 Public or Medicaid 0.66 (0.61–0.71) 1.08 (1.05–1.11)
 Unknown 0.26 (0.22–0.31) 0.37 (0.35–0.40)
Patient SES distribution of reporting hospitalb
 >50% of patients in quintiles 1–2 1.12 (1.05–1.20) 1.49 (1.44–1.53)
 >50% of patients in quintiles 4–5 1 [Reference] 1 [Reference]
 Mixed distribution 1.05 (1.00–1.10) 1.32 (1.28–1.35)
Received care at an NCI- designated cancer center
 No 1 [Reference] 1 [Reference]
 Yes 1.13 (1.04–1.22) 0.81 (0.77–0.85)
Year of cancer diagnosis
 1998–2004 1 [Reference] 1 [Reference]
 2005–2011 2.73 (2.61–2.86) 0.84 (0.82–0.86)
Abbreviations: ER, estrogen receptor; NCI, National Cancer Institute; PR, progesterone receptor; SES, socioeconomic status.
aOdds ratios based on polytomous logistic regression modeling. Model covariates were age, race/ethnicity, tumor size, grade, ER/PR status, nodal 
status, histology, receipt of adjuvant treatments including chemotherapy and radiation, neighborhood SES quintile, marital status, insurance status, 
SES composition of patients at the reporting hospital, care at an NCI-designated cancer center, and year of diagnosis.
b
Distribution based on statewide quintiles.
cP value for trend of SES was <.001 for both bilateral mastectomy and unilateral mastectomy compared with breast-conserving surgery with 
radiation.
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Table 4
Multiple Regression Hazard Ratios for Associations of Patient and Clinical Characteristics With Overall 
Mortality, Stages 0–III Breast Cancer, 1998–2010, Californiaa
Variable Deceased Patients Total Patients HR (95% CI)
Surgical procedure
 Bilateral mastectomy 635 9907 1.02 (0.94–1.11)
 Breast-conserving surgery with radiation 9949 96 462 1 [Reference]
 Unilateral mastectomy 13 699 68 548 1.35 (1.32–1.39)
Race/ethnicity
 Chinese 383 4787 0.70 (0.63–0.78)
 Filipina 529 6150 0.69 (0.63–0.75)
 Hispanic 2982 26 035 0.81 (0.77–0.84)
 Japanese 244 2263 0.70 (0.62–0.80)
 Non-Hispanic American Indian/other/unknown 150 1378 0.85 (0.72–1.00)
 Non-Hispanic black 1701 9112 1.12 (1.06–1.17)
 Non-Hispanic white 17 782 117 853 1 [Reference]
 Other Asian/Pacific Islander 512 7339 0.67 (0.61–0.73)
Age at diagnosis, y
 <40 1124 9341 1.11 (1.04–1.19)
 40–49 2503 34 878 0.82 (0.78–0.86)
 50–64 5621 68 104 1 [Reference]
 ≥65 15 035 62 594 2.65 (2.56–2.75)
Tumor size
 Per centimeter NA NA 1.23 (1.21–1.25)
Lymph node involvement
 Negative 14 327 126 165 1 [Reference]
 Positive 9956 48 752 1.46 (1.40–1.51)
Histology
 Ductal 20 561 149 278 1 [Reference]
 Lobular or with lobular component 1961 12 403 0.89 (0.84–0.93)
 Other 1761 13 236 0.92 (0.87–0.96)
Grade
 I 3825 36 593 1 [Reference]
 II 8919 70 377 1.15 (1.11–1.20)
 III 9828 58 247 1.49 (1.43–1.55)
 Unknown 1711 9700 1.23 (1.16–1.30)
ER/PR status
 Negative 4992 26 685 1.48 (1.43–1.53)
 Positive 15 375 125 955 1 [Reference]
 Unknown or borderline 3916 22 277 1.11 (1.07–1.15)
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Variable Deceased Patients Total Patients HR (95% CI)
Adjuvant treatment, chemotherapy, and/or radiation
 No 15 336 109 699 1 [Reference]
 Yes 8947 65 218 0.78 (0.76–0.81)
Neighborhood SES quintileb,c
 1 (lowest) 3308 18 484 1 [Reference]
 2 4758 28 329 0.97 (0.92–1.01)
 3 5394 35 740 0.90 (0.86–0.94)
 4 5564 42 120 0.85 (0.81–0.89)
 5 5259 50 244 0.73 (0.70–0.77)
Marital status
 Married 11 432 104 647 1 [Reference]
 Not married 12 438 67 098 1.36 (1.33–1.40)
 Unknown 413 3172 1.18 (1.07–1.30)
Insurance status
 Medicare 5229 22 445 1.22 (1.18–1.26)
 Military 158 1487 1.12 (0.96–1.31)
 Not insured or self-pay 187 1408 1.10 (0.95–1.27)
 Private 11 957 113 347 1 [Reference]
 Public or Medicaid 5892 29 746 1.25 (1.21–1.29)
 Unknown 860 6484 0.92 (0.86–0.99)
Patient SES distribution of reporting hospitalb
 >50% of patients in quintiles 4–5 10 471 89 573 1 [Reference]
 >50% of patients in quintiles 1–2 5555 31 015 1.12 (1.08–1.16)
 Mixed distribution 8257 54 329 1.07 (1.04–1.11)
Received care at an NCI-designated cancer center
 No 23 494 166 025 1 [Reference]
 Yes 789 8892 0.82 (0.76–0.88)
Year of cancer diagnosis
 Per year NA NA 0.87 (0.87–0.88)
Abbreviations: ER, estrogen receptor; HR, hazard ratio; NA, not applicable; NCI, National Cancer Institute; PR, progesterone receptor; SES, 
socioeconomic status.
a
Mortality analyses excluded women diagnosed after 2010 because of incomplete mortality data for 2011. Model covariates included age, race/
ethnicity, tumor size, grade, and ER/PR status, nodal status, histology, receipt of adjuvant treatments including chemotherapy and radiation, 
neighborhood SES quintile, marital status, insurance status, SES composition of patients at the reporting hospital, care at an NCI-designated cancer 
center, and year of diagnosis. Models were stratified by American Joint Committee on Cancer stage.
b
Distribution based on statewide quintiles.
cP value for trend of SES was <.001.
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Table 5
Multiple Regression Hazard Ratios for Associations of Patient and Clinical Characteristics With Breast 
Cancer–Specific Mortality, Stages 0–III Breast Cancer, 1998–2010, Californiaa
Variable Deceased Patients Total Patients HR (95% CI)
Surgical procedure
 Bilateral mastectomy 392 9907 1.09 (0.98–1.21)
 Breast-conserving surgery with radiation 3620 96 462 1 [Reference]
 Unilateral mastectomy 6115 68 548 1.29 (1.23–1.35)
Race/ethnicity
 Chinese 210 4787 0.85 (0.74–0.97)
 Filipina 315 6150 0.83 (0.74–0.94)
 Hispanic 1703 26 035 0.90 (0.85–0.95)
 Japanese 80 2263 0.70 (0.56–0.88)
 Non-Hispanic American Indian/other/unknown 73 1378 1.06 (0.84–1.34)
 Non-Hispanic black 896 9112 1.22 (1.14–1.32)
 Non-Hispanic white 6529 117 853 1 [Reference]
 Other Asian/Pacific Islander 321 7339 0.81 (0.72–0.90)
Age at diagnosis, y
 <40 1027 9341 1.32 (1.22–1.41)
 40–49 1995 34 878 0.97 (0.92–1.03)
 50–64 3311 68 104 1 [Reference]
 ≥65 3794 62 594 1.43 (1.35–1.51)
Tumor size
 Per centimeter NA NA 1.33 (1.30–1.36)
Lymph node involvement
 Negative 3905 126 165 1 [Reference]
 Positive 6222 48 752 1.96 (1.85–2.07)
Histology
 Ductal 8915 149 278 1 [Reference]
 Lobular or with lobular component 684 12 403 0.98 (0.90–1.07)
 Other 528 13 236 0.78 (0.71–0.85)
Grade
 I 634 36 593 1 [Reference]
 II 3071 70 377 1.87 (1.71–2.04)
 III 5953 58 247 3.12 (2.86–3.41)
 Unknown 469 9700 1.82 (1.60–2.06)
ER/PR status
 Negative 3295 26 685 1.80 (1.71–1.88)
 Positive 5622 125 955 1 [Reference]
 Unknown or borderline 1210 22 277 1.12 (1.05–1.20)
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Variable Deceased Patients Total Patients HR (95% CI)
Adjuvant treatment, chemotherapy, and/or radiation
 No 3742 109 699 1 [Reference]
 Yes 6385 65 218 1.10 (1.05–1.16)
Neighborhood SES quintileb,c
 1 (lowest) 1506 18 484 1 [Reference]
 2 2007 28 329 0.99 (0.93–1.06)
 3 2181 35 740 0.93 (0.87–1.00)
 4 2257 42 120 0.89 (0.83–0.96)
 5 2176 50 244 0.80 (0.74–0.86)
Marital status
 Married 5559 104 647 1 [Reference]
 Not married 4393 67 098 1.13 (1.08–1.18)
 Unknown 175 3172 1.08 (0.93–1.26)
Insurance status
 Medicare 1362 22 445 1.23 (1.15–1.31)
 Military 84 1487 1.07 (0.86–1.33)
 Not insured or self-pay 120 1408 1.09 (0.91–1.31)
 Private 5831 113 347 1 [Reference]
 Public or Medicaid 2368 29 746 1.30 (1.23–1.37)
 Unknown 362 6484 0.80 (0.72–0.89)
Patient SES distribution of reporting hospitalb
 >50% of patients in quintiles 4–5 4316 89 573 1 [Reference]
 >50% of patients in quintiles 1–2 2456 31 015 1.12 (1.05–1.18)
 Mixed distribution 3355 54 329 1.07 (1.02–1.12)
Received care at an NCI-designated cancer center
 No 9731 166 025 1 [Reference]
 Yes 396 8892 0.87 (0.78–0.96)
Year of cancer diagnosis
 Per year Not applicable Not applicable 0.87 (0.87–0.88)
Abbreviations: HR, hazard ratio; NA, not applicable; NCI, National Cancer Institute; SES, socioeconomic status.
a
Mortality analyses excluded women diagnosed after 2010 because of incomplete mortality data for 2011. Model covariates included age, race/
ethnicity, tumor size, grade, and ER/PR status, nodal status, histology, receipt of adjuvant treatments including chemotherapy and radiation, 
neighborhood SES quintile, marital status, insurance status, SES composition of patients at the reporting hospital, care at an NCI-designated cancer 
center, and year of diagnosis. Models were stratified by American Joint Committee on Cancer stage.
b
Distribution based on statewide quintiles.
cP value for trend of SES was <.001.
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Table 6
Propensity Score Analysis of Overall Mortality, Showing Average Effect of an Alternative Surgical Procedure 
on Patients Treated With a Specific Surgical Procedure (Average Treatment Effect of Those Treated)
Surgical Treatment and Alternatives Hazard Ratio for Mortality (95% CI)
Bilateral mastectomy
 vs unilateral mastectomy 1.23 (1.13–1.33)
 vs breast-conserving surgery with radiation 0.94 (0.86–1.02)
Breast-conserving surgery with radiation
 vs bilateral mastectomy 1.13 (1.00–1.28)
 vs unilateral mastectomy 1.27 (1.23–1.31)
Unilateral mastectomy
 vs bilateral mastectomy 0.93 (0.83–1.04)
 vs breast-conserving surgery with radiation 0.81 (0.78–0.84)
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